Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News How Spruce Biosciences’ tralesinidase alfa could become the first disease-modifying therapy for Sanfilippo syndrome type B Find out how Spruce Biosciences is redefining enzyme replacement therapy with its FDA-designated tralesinidase alfa for Sanfilippo syndrome type B. bySoujanya RaviOctober 6, 2025